6-K 1 f6k_022916.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

February 29, 2016

________________

 

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 

DK- 2880, Bagsvaerd 

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F [X]           Form 40-F [  ]

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes [  ]            No [X]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________

 

 

 

  

Novo Nordisk A/S – Share repurchase programme

 

 

Bagsværd, Denmark, 29 February 2016 - On 3 February 2016, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 3 February 2016.

 

Under the programme initiated 3 February 2016, Novo Nordisk will repurchase B shares for an amount up to DKK 3.3 billion in the period from 3 February 2016 to 27 April 2016.

 

Since the announcement as of 22 February 2016, the following transactions have been made under the programme:

 

    Number of
B shares
    Average
purchase price
    Transaction
value, DKK
 
Accumulated, last announcement   2,310,000         763,780,137 
22 February 2016   175,000    347.90    60,882,780 
23 February 2016   165,000    352.22    58,116,597 
24 February 2016   175,000    343.97    60,195,328 
25 February 2016   170,000    349.68    59,445,005 
26 February 2016   170,000    355.38    60,414,753 
                
Accumulated under the programme   3,165,000         1,062,834,599 

 

With the transactions stated above, Novo Nordisk owns a total of 57,788,102 B shares of DKK 0.20, corresponding to 2.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,600,000,000 including treasury shares.

 

 

Page 2 of 2

 

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14 billion during a 12-month period beginning 3 February 2016. As of 26 February 2016, Novo Nordisk has repurchased a total of 3,165,000 B shares equal to a transaction value of DKK 1,062,834,599.

 

 

Further information

Media:
Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com
     
Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Kasper Veje +45 3079 8519 kpvj@novonordisk.com

 

 

 

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

 

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

    Company announcement No 19 / 2016

 

 


 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: February 29, 2016

 

NOVO NORDISK A/S

 

Lars Rebien Sørensen,

Chief Executive Officer